No more killing the good bacteria along with the bad. An antibiotic "smart bomb" can identify specific strains of bacteria and sever their DNA, eliminating the infection and reducing multi-drug resistant bacteria.
The new approach works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When those CRISPR RNAs find a match, they unleash Cas proteins that cut the DNA.
The researchers have demonstrated that designing CRISPR RNAs to target DNA sequences in the bacteria themselves causes bacterial suicide, as a bacterium's CRISPR-Cas system attacks its own DNA.
"Conventional antibiotic treatments kill both 'good' and 'bad' bacteria, leading to unintended consequences, such as opportunistic infections," says senior author Dr. Chase Beisel, an assistant professor of chemical and biomolecular engineering at North Carolina State University. "What we've shown in this new work is that it is possible to selectively remove specific strains of bacteria without affecting populations of good bacteria.
"In lab testing, we found that this approach removes the targeted bacteria. We're still trying to understand precisely how severing the DNA leads to elimination of the bacteria. However, we're encouraged by the ease in specifically targeting different bacteria and the potency of elimination."
The researchers tested the approach in controlled cultures with different combinations of bacteria present, and were able to eliminate only the targeted strain. "For example, we were able to eliminate Salmonella in a culture without affecting good bacteria normally found in the digestive tract," Beisel says.
The researchers were also able to demonstrate the precision of the technique by eliminating one strain of a species, but not another strain of the same species which shares 99 percent of the same DNA.
Another benefit of the approach, Beisel says, is that "by targeting specific DNA strands through the CRISPR-Cas system, we're able to bypass the mechanisms underlying the many examples of antibiotic resistance."
The researchers are currently working to develop effective methods for delivering the CRISPR RNAs in clinical settings.
"This sets the stage for next-generation antibiotics using programmable CRISPR-Cas systems," says co-author Dr. Rodolphe Barrangou, an associate professor of food, bioprocessing and nutrition sciences at NC State.